TY - JOUR A1 - Schlör, Anja A1 - Hirschberg, Stefan A1 - Ben Amor, Ghada A1 - Meister, Toni Luise A1 - Arora, Prerna A1 - Pöhlmann, Stefan A1 - Hoffmann, Markus A1 - Pfänder, Stephanie A1 - Eddin, Omar Kamal A1 - Kamhieh-Milz, Julian A1 - Hanack, Katja T1 - SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications JF - Frontiers in Immunology N2 - Introduction: The ongoing COVID-19 pandemic situation caused by SARS-CoV-2 and variants of concern such as B.1.617.2 (Delta) and recently, B.1.1.529 (Omicron) is posing multiple challenges to humanity. The rapid evolution of the virus requires adaptation of diagnostic and therapeutic applications. Objectives: In this study, we describe camelid heavy-chain-only antibodies (hcAb) as useful tools for novel in vitro diagnostic assays and for therapeutic applications due to their neutralizing capacity. Methods: Five antibody candidates were selected out of a naïve camelid library by phage display and expressed as full length IgG2 antibodies. The antibodies were characterized by Western blot, enzyme-linked immunosorbent assays, surface plasmon resonance with regard to their specificity to the recombinant SARS-CoV-2 Spike protein and to SARS-CoV-2 virus-like particles. Neutralization assays were performed with authentic SARS-CoV-2 and pseudotyped viruses (wildtype and Omicron). Results: All antibodies efficiently detect recombinant SARS-CoV-2 Spike protein and SARS-CoV-2 virus-like particles in different ELISA setups. The best combination was shown with hcAb B10 as catcher antibody and HRP-conjugated hcAb A7.2 as the detection antibody. Further, four out of five antibodies potently neutralized authentic wildtype SARS-CoV-2 and particles pseudotyped with the SARS-CoV-2 Spike proteins of the wildtype and Omicron variant, sublineage BA.1 at concentrations between 0.1 and 0.35 ng/mL (ND50). Conclusion: Collectively, we report novel camelid hcAbs suitable for diagnostics and potential therapy. KW - camelid heavy-chain-only antibodies KW - single domain antibodies KW - nanobodies KW - SARS-CoV-2 KW - neutralization KW - Omicron Y1 - 2022 U6 - https://doi.org/10.3389/fimmu.2022.930975 SN - 1664-3224 SP - 1 EP - 14 PB - Frontiers Media SA CY - Lausanne, Schweiz ER - TY - JOUR A1 - Urbach, Dietmar A1 - Awiszus, Friedemann A1 - Leiß, Sven A1 - Venton, Tamsin A1 - De Specht, Alexander Vincent A1 - Apfelbacher, Christian T1 - Associations of medications with lower odds of typical COVID-19 symptoms BT - cross-sectional symptom surveillance study JF - JMIR public health and surveillance N2 - Background: As the COVID-19 pandemic continues to spread across the globe, the search for an effective medication to treat the symptoms of COVID-19 continues as well. It would be desirable to identify a medication that is already in use for another condition and whose side effect profile and safety data are already known and approved. Objective: The objective of this study was to evaluate the effect of different medications on typical COVID-19 symptoms by using data from an online surveillance survey. Methods: Between early April and late-July 2020, a total of 3654 individuals in Lower Saxony, Germany, participated in an online symptom-tracking survey conducted through the app covid-nein-danke.de. The questionnaire comprised items on typical COVID-19 symptoms, age range, gender, employment in patient-facing healthcare, housing status, postal code, previous illnesses, permanent medication, vaccination status, results of reverse transcription polymerase chain reaction (RT-PCR) and antibody tests for COVID-19 diagnosis, and consequent COVID-19 treatment if applicable. Odds ratio estimates with corresponding 95% CIs were computed for each medication and symptom by using logistic regression models. Results: Data analysis suggested a statistically significant inverse relationship between typical COVID-19 symptoms self-reported by the participants and self-reported statin therapy and, to a lesser extent, antihypertensive therapy. When COVID-19 diagnosis was based on restrictive symptom criteria (ie, presence of 4 out of 7 symptoms) or a positive RT-PCR test, a statistically significant association was found solely for statins (odds ratio 0.28, 95% CI 0.1-0.78). Conclusions: Individuals taking statin medication are more likely to have asymptomatic COVID-19, in which case they may be at an increased risk of transmitting the disease unknowingly. We suggest that the results of this study be incorporated into symptoms-based surveillance and decision-making protocols in regard to COVID-19 management. Whether statin therapy has a beneficial effect in combating COVID-19 cannot be deduced based on our findings and should be investigated by further study. KW - COVID-19 KW - SARS-CoV-2 KW - statins KW - antihypertensives KW - surveillance KW - hydroxymethyl-glutaryl-coenzyme A reductase inhibitors;online survey Y1 - 2020 U6 - https://doi.org/10.2196/22521 SN - 2369-2960 VL - 6 IS - 4 PB - JMIR Publications CY - Toronto ER -